Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;44(12):3121-3137.
doi: 10.1111/liv.16065. Epub 2024 Sep 9.

Drug-induced liver injury related to gene therapy: A new challenge to be managed

Affiliations
Review

Drug-induced liver injury related to gene therapy: A new challenge to be managed

Dominique Larrey et al. Liver Int. 2024 Dec.

Abstract

Gene therapy is being successfully developed for the treatment of several genetic disorders. Various methods of gene transfer have been developed to enable the production of the deficient enzyme or protein. One of the most important is adeno-associated virus vectors, which have been shown to be viable for use in in vivo gene therapy. Several gene therapies have already been approved. They are also promising for acquired diseases. Important examples include gene therapy for haemophilia A and B, X-linked myotubular myopathy, spinal muscular atrophy and several liver diseases such as Criggler-Najjar disease, alpha-1 antitrypsin deficiency and Fabry disease. However, the introduction of a foreign compound into hepatocytes leads to hepatic reactions with heterogeneous phenotypic expression and a wide spectrum of severity, ranging from mild transaminase elevation to acute liver failure. Several mechanisms appear to be involved in liver injury, including an immune response, but also direct toxicity depending on the method of gene transfer. As a result, the incidence, expression and severity of liver injury vary from indication to indication and from patient to patient. Patients treated for haemophilia A are more prone to transaminase elevation than those treated for haemophilia B. Corticosteroids are successfully used to correct liver reactions but also to prevent degradation of the transferred gene and loss of therapeutic activity. The aim of this review is to describe the risk of liver injury according to the indication for gene therapy and the short- and long-term management currently proposed to prevent or correct liver reactions in clinical practice.

Keywords: adeno‐associated virus; drug‐induced liver injury; gene therapy; immuno‐suppression; management.

PubMed Disclaimer

References

REFERENCES

    1. Palomo GM, Pose‐Boiazian T, Nauman‐Winter F, et al. The European landscape for gene therapies in orphan diseases: 6‐year experience with the EMA Committee for orphan medicinal products. Mol Ther. 2023;31:3414‐3423. doi:10.1016/j.ymthe.2023.09.020
    1. Adair JE, Androski L, Bayigga L, et al. Towards access for all: 1st working group report for the global gene Therapy initiative (GGTI). Gene Ther. 2023;30:216‐221. doi:10.1038/s41434-021-00284-4
    1. Chancellor D, Barrett D, Nguyen‐Jatkoe L, Millington S, Eckhardt F. The state of cell and gene therapy in 2023. Mol Ther. 2023;31:3376‐3388. doi:10.1016/j.ymthe.2023.11.001
    1. Zabaleta N, Unzu C, Weber ND, Gonzalez‐Aseguinolaza G. Gene therapy for liver diseases – progress and challenges. Nat Rev Gastroenterol Hepatol. 2023;20:288‐305.
    1. Baruteau J, Keshavan N, Vendetti CP. Mission possible: gene therapy for inherited diseases. J Inherit Metab Dis. 2024;47:5‐6. doi:10.1002/jimd.12708

MeSH terms